US FDA’s October Outlook: Xphozah After Dispute, Santhera’s New Steroid For DMD, & Plenty Of Pfizer

Pfizer Inc. can claim two of the three novel agents on the FDA’s user fee calendar for the month of October 2023, the Pink Sheet’s US FDA Performance Tracker shows.

Joining Pfizer’s oral ulcerative colitis therapy etrasimod and pentavalent meningococcal vaccine in the novel review queue is a candidate from a small sponsor, Santhera